Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
| Condition | Lung Carcinoma |
|---|---|
| Phase | N/A |
| Sponsor | M.D. Anderson Cancer Center |
| Status | Active, not recruiting |
| Enrollment | 135 participants |
| Interventions | Nicotine Replacement |
| Start date | Mar 7, 2022 |
| Completion date | Oct 17, 2025 |
| Results posted | Aug 5, 2026 |
Summary
This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators of the potential risks and benefits of switching smokers at high risk for lung cancer to electronic cigarettes. This research also may help inform the Food and Drug Administration (FDA) how best to regulate e-cigarettes with the goal of improving public health.
Combustible Cigarettes Per Day
| Electronic Cigarettes Arm | 15.36 ± 8.93 cigarettes per day |
|---|---|
| Electronic Cigarettes Arm | 7.52 ± 7.54 cigarettes per day |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)